Track Your Inflammation

When you have IBD, your healthcare team monitors inflammatory markers, objective measurements that indicate how much inflammation is present in your body. These markers are important tools for assessing disease activity, but understanding their strengths and limitations helps you interpret your lab results with appropriate context. Three commonly tracked markers are fecal calprotectin, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR).

Fecal calprotectin is a protein released by white blood cells that shows up in stool when the gut lining is inflamed. It does not measure inflammation directly, but it tracks it more closely than anything else you can do without a scope. Roughly, results under 50 µg/g point away from active inflammation and results over 250 µg/g point toward it. Treat those numbers as landmarks rather than as a line in the sand: published cut-offs range from 50 to 250 µg/g depending on the guideline, and different laboratories use different assays, so a value from one lab is not always interchangeable with a value from another. Values in between are genuinely uncertain and are a reason to ask your team what they make of it, not a reason to relax. Calprotectin also rises for reasons other than IBD, including NSAIDs such as ibuprofen, proton pump inhibitors, and gut infections.

CRP and ESR are systemic markers that measure inflammation anywhere in your body. CRP is made by the liver in response to inflammation; ESR measures how quickly red blood cells settle in a tube, a process that inflammation speeds up but that anemia, age, sex and pregnancy also affect, and anemia is common in IBD. Both are less specific to the gut than calprotectin, and both can be moved by infection, other autoimmune disease, cardiovascular disease and obesity.

The most important limitation is where your disease is. These markers perform much worse in Crohn's disease confined to the ileum, the end of the small bowel. In the one study that looked at isolated small bowel disease on its own, calprotectin did not track disease activity at all, while it performed well in the same study's patients with colonic Crohn's and ulcerative colitis. Across studies that report accuracy by location, the numbers are scattered enough that no dependable figure can be quoted. CRP behaves the same way: it correlates with activity least well in ileal disease of any Crohn's location. If your disease is ileal, a normal marker does not reliably mean your disease is quiet, and imaging or a scope may be the only way to know. The outstanding challenges page goes through the evidence with sources. American Gastroenterological Association guidance is that in Crohn's disease that looks quiet without a recent scope, endoscopic evaluation is preferred over relying on calprotectin or CRP alone.

A single lab result is like a photograph: it captures a moment, not the whole story. Markers do vary between tests, both because assays vary and because disease activity does. What they do not do is swing around with how well you slept or how stressed your week was, so a rise is not something to explain away. Direction matters as much as the single number. A calprotectin of 180 µg/g falling from 400 three months ago is a different situation from the same 180 climbing from 80 last month, and a value that sits in the 150 to 200 range month after month is not reassuring, it is a reason to ask what is driving it. Bring the trend to your gastroenterologist rather than deciding what it means on your own, and do not change a dose or stop a drug on the strength of a lab value.

This is why maintaining a log of your lab results over time is invaluable. Create a simple spreadsheet with dates and your key markers (fecal calprotectin, CRP, ESR if available) and track them over months and years. Note when you started new medications, made dietary changes, or experienced significant life stressors, and see if your markers responded accordingly. Over time, you'll develop intuition about what your numbers mean specifically for you. You might notice that your markers correlate strongly with your symptoms, or you might discover that you can feel reasonably well despite somewhat elevated lab values. You'll learn whether gradual increase warrants a treatment change or whether your disease tends to plateau at certain levels before improving. This longitudinal perspective is far more useful than any single test result.

Laboratory markers are objective measurements, and that objectivity is valuable, but they are not the whole truth about your disease. Some people with raised markers feel well, while others with normal markers struggle with symptoms. This clinical-biochemical disconnect happens because the relationship between inflammation and how you feel is not one to one. You might have microscopic inflammation that is not yet causing symptoms, or symptoms that reflect inflammation which is healing but has not fully settled on tests. Symptoms can also come from damage rather than activity: a stricture that narrows the bowel, scarring left behind by previous inflammation, bile acid diarrhea after an ileal resection, or bacterial overgrowth. Each of those is a real, physical cause with its own treatment, and each is worth investigating rather than accepting as something you have to live with.

This is why the most complete picture of your disease comes from combining lab markers with your symptom experience and your doctor's clinical assessment. Report your symptoms honestly and thoroughly, don't downplay how you're actually feeling because your lab values look acceptable, and don't assume you're in remission just because you feel good if your markers tell a different story. When your symptoms and your lab results diverge, that disconnect is important information that should prompt a conversation with your doctor. It might mean you need additional investigation, a medication adjustment, or simply acknowledgment that your disease is more complex than the markers alone suggest. Your experience matters as much as your lab values, and the best treatment decisions come from honoring both.